Companies

Booster dose for Cipla’s US business

Nalinakanthi V | Updated on January 22, 2018 Published on September 04, 2015

cipla



Cipla’s decision to acquire two US-based generic drug makers — InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc — will benefit the former on three counts.

One, the acquisition will help Cipla widen its footprint in the US and boost the company’s revenues from this geography. InvaGen and Exelan reported combined revenue of $275 million (₹1,829 crore) for the 12-month period ended June 2015.

This is about 16 per cent of the Cipla’s consolidated revenues in 2014-15.

Second, given the healthy operating profit margin in the US, the acquisition is expected to margin accretive for Cipla, once completed.

The combined operating profit margin of InvaGen and Exelan is estimated to be around 20.6 per cent for the 12-month period ended June 2015.

This is higher than the 19 per cent operating margin reported by Cipla on a consolidated basis in 2014-15. Hence, the acquisition should rev up the company’s blended operating profit margin.

Finally, besides geographical expansion, the acquisition will also help the company diversify its product offering across therapeutic categories. InvaGen has a diversified pipeline of about 40 drugs used to treat ailments such as cardio-vascular, neurological disorders, diabetes and infection, which have been approved by the US Food and Drug Administration.

Of these, 32 products are currently sold in the market. It has a pipeline of 30 products, which are pending approval and likely be commercialised over the next four years.

InvaGen is the first generic filer for five products with a cumulative market size of $8 billion. The company should enjoy exclusive marketing right for six months; this can lift Cipla’s revenues and profit over the next three years. These acquisitions will give the company access to large capacity manufacturing base in Hauppauge, NY and Research and Development infrastructure in the US, which can be used to file other products for the US market.

Published on September 04, 2015

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.